Etevritamab

Description

Etevritamab AMG-596 is a bispecific T-cell engager targeting EGFRvIII and CD3. Etevritamab can simultaneously bind to the tumor-specific antigen EGFRvIII on glioblastoma multiforme and CD3 on T cells, thereby activating T-cell proliferation and secretion of cytotoxic substances to induce lysis of the bound tumor cells. Etevritamab can be used for the research of tumors such as glioblastoma multiforme.